The increase in the erythropoietin level achieved by SGLT2i treatment appears to involve the suppression of hepcidin and ferritin and an increase of transferrin receptor protein 1 (101–103), which would correct anemia and improve clinical outcomes (104). The gene discussed is TFRC; the disease is anemia.